Presentation – Risk in Multiple Sclerosis Treatment

Risk in Multiple Sclerosis Treatment by Maura Pugliatti & Carlo Pozzilli

24 April 2021, Expert meeting. : Risk assessment in the treatment of MS patients is this first of a two-part ParadigMS series by Professors Maura Pugliatti and Carlo Pozzilli. They share their strategies for identifying treatment risks based on individual patient characteristics.

ABSTRACT

Every MS patient is different, and prescribing the correct treatment based on MS disease characteristics and patient-related factors (comorbidities, desire for children, etc) is no trivial matter. Anticipating potential complications associated with each disease-modifying therapy and taking the correct action before adverse events occur is a major challenge facing MS neurologists.
In this first of a two-part ParadigMS series, Professors Maura Pugliatti and Carlo Pozzilli will share with you their strategies for identifying treatment risks based on individual patient characteristics. This presentation will provide an excellent educational resource for all neurologists aiming to further their knowledge and skill in relation to risk identification, and in this way improve the overall patient experience. Details on risk mitigation will be provided in part two of this series.

MAURA PUGLIATTI
Maura PUGLIATTI, MD, PhD is Full Professor of Neurology at the University of Ferrara, Director of the University Hospital Unit of Clinical Neurology, S. Anna Hospital, Ferrara, Italy. She is also Director of the Residency School of Neurology at the same University. In 2007 she took a PhD and in 2007-10 was Research Fellow at the Dept. of Public Health and Primary Health Care, University of Bergen, Norway, actively coordinating a large multi-center case-control study on multiple sclerosis and environmental risk factors. Since 2011 she is Adjunct Professor at the Dept. of Clinical Medicine, McGill University, Montreal, Canada within collaborative research in MS epidemiology. She has been Visiting Professor at the University of Bergen (Erasmus Teaching Staff Mobility program to medical students, 2010-12), University of Belgrade, Serbia (to PhD student, 2015), and has been a faculty member of the PhD School in at the University of Medicine and Pharmacy, Cluj Napoca, Romania, since 2016. In 2008-14 she was Chair of the EFNS Scientist Panel of Neuroepidemiology and Public Health, and has co-chaired the same Panel for the European Academy of Neurology in 2015-18. She is a member of ParadigMS Foundation founders.
Her main research areas are multiple sclerosis, epidemiology of amyotrophic lateral sclerosis, through collaborative research at national and international level. She is author of 137 papers in peer-reviewed scientific journals, has a total impact factor > 500 and H-index=37.

CARLO POZZILLI

Professor Pozzilli studied at the University of Rome “La Sapienza”. He then moved to the Hammersmith Hospital in London, UK, to take up a research post in 1980.In 1983, he became a Board Certified Neurologist at the University of Rome. In 1986 obtained a research grant in Neuroimaging at the Tohoku University, Sendai Japan.In 1987, he was awarded a PhD in Clinical Neurosciences by the University of Rome, where he became Full Professor in 2006. In 2002 he funded and become Director of the Multiple Sclerosis (MS) Center of OspedaleS.Andrea, University of Rome which is his actual position.

Professor Pozzilli’s fields of interest include the clinical aspects and treatment of MS; he has published more than 350 papers and reviews on these subjects.
Professor Pozzilli is a member of several National and International Societies.

He has participated as a first investigator in at least 250 multicentre clinical trials on patients with MS. He was also member of the Steering Committee and Advisory Board inseveral multicentre trials.




Media

Details

  • Directors

    ParadigMS
  • Author(s)

    Prof Maura Pugliatti & Prof Carlo Pozzilli
  • Country

    Belgium
  • Release Date

    April 24, 2021
  • Views


You Might Also Like

Article – Microbiome in Multiple Sclerosis

Presentation – The Microbiome in Multiple Sclerosis


Educational slide decks
endorsed by experts

Minimum two MS experts collaborate to produce an educational slide deck. These slide decks are presented (live) to ParadigMS members, peer reviewed and updated.
The slide decks are published on the ParadigMS website “on behalf of ParadigMS”.

Consensus publications

Based on the slide decks, publications are produced. These publications are peer reviewed and published as consensus publications.

Regional and national educational events

Regional (fe: Scandinavian countries, Benelux, …) or national events where state-of-the-art science is transferred to general neurologists and other care givers (nurses, etc) that are confronted with MS in their day to day practice.

Web-based educational tools and resources

Webinars can complement the educational events.

Medical education (ME) programs

The educational slide decks, events and webinars can be important building blocks of accredited educational programs.

FAQs

Do subscriptions auto-renew?
Your subscription will automatically renew on a monthly or yearly basis, depending on the plan you have chosen. If you cancel your plan, it will not renew at the end of your subscription cycle. It will end once the period you have paid for is over.
What happens if I subscribe as a healthcare practitioner if I am not a healthcare practitioner?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, you will be banned immediately from the community and could be liable to prosecution.
How can I cancel my trial or subscription?
You can cancel your trial or subscription in your account settings. If you cancel during the trial period you will not be charged.

Terms and Conditions

All the Terms and Conditions of the ParadigMS Foundation Website can be downloaded here.

Subscribe to our bi-annual Newsletter

ParadigMS does not send eNewsletters that contain advertisements and we do not share your contact details with sponsors (unless we received your explicit consent)